Of the thousands of compounds active against a target, how many typically pass preclinical testing?

Question

BlackTom AI · Accepted Answer

Question restatement: The prompt asks, among thousands of compounds active against a target, how many typically pass preclinical testing?

Option a. 10–50: This range is higher than commonly cited preclinical pass rates, which are a small fraction of the initial pool. It overstates the progression from discovery to preclinical success.

Option b. 1–5: This range aligns with typical screening-to-preclinical success stories in drug discovery, where only a handful of compounds out of thousands advance due to factors like efficacy, selectivity, toxicity, and pharmacokinetics. It reflects the very selective bottleneck at preclinical advancement.

Option c. 5–10: While closer to reality than some ranges, this still represents a larger fraction than is commonly observed; the attrition rate is very steep, and 5–10 out of thousands would be unusually optimistic given typical discovery pipeline challenges.

Option d. 50-100: This option vastly overestimates the number that survive preclinical testing from a large initial pool; advancing 50–100 compounds would imply a much higher success rate through preclinical screening than is generally observed, given safety, efficacy, and ADME/Tox hurdles.

Why the correct option is correct (b): In early drug discovery, many compounds are identified, but only a tiny subset demonstrates the required potency, selectivity, safety, and drug-like properties to proceed to preclinical studies. The typical attrition rate at this stage is high, often yielding only about a dozen or fewer candidates per thousands initially identified, with 1–5 being a common, cautious estimate of those that advance.

Why the other options are incorrect (a, c, d):
- a incorrect because it overestimates the number that pass to preclinical testing, not accounting for stringent safety and efficacy filters.
- c incorrect since it still overestimates progression likelihood relative to the steep drop-off seen in preclinical qualification.
- d incorrect because it grossly overstates the viable pool remaining after initial screening, contradicting common industry experience of tight selection for preclinical progression.

In summary, option b reflects the widely acknowledged reality that only a small handful of compounds out of thousands advance past preclinical testing due to rigorous requirements across efficacy, safety, and pharmacokinetic criteria.

Of the thousands of compounds active against a target, how many typically pass preclinical testing?Single choice

Similar Questions

Which one of the following statements about modern day drug discovery is INCORRECT?

Which one of the following statements regarding early drug discovery approaches is correct?

What was the goal of Pfizer chemists when they developed the drug UK-92.480?

What is the effect on the financial statements when a company fails to adjust the unearned revenue account for revenues earned at year-end?

Which of the following correctly describes the effects of initially recording prepaid insurance expense when cash is paid to purchase an insurance policy?

Which of the following does not correctly describe an adjusting journal entry that debits rent expense and credits prepaid rent?

More Practical Tools for Students Powered by AI Study Helper

Homework AI Solver

Stylized AI Paper Writer

Plagiarism Checker Assistant

Citation AI Academic Writing Tool

In-Class Translation Assistant

AI Note Generator

AI Quiz Answers

Past Exam Questions from University Test Bank

Smart Practice Assistant

Adaptive Practice

Making Your Study Simpler